Vicebio raises $100 million for next-gen respiratory virus vaccines

British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses.

The funding was led by TCGX and included investments from Goldman Sachs Alternatives, Avoro Ventures, and venBio, as well as continued support from UniQuest and founding investor Medicxi.

Chief executive Emmanuel Hanon said: "The support from these high-caliber investors underscores the robust data package we have generated for VXB-241, highlighting the significant potential of our proprietary Molecular Clamp technology.”